
INO Stock Rose 4.69% on Friday, Inovio Partners with IVI and KNIH to Test COVID-19 Vaccine
Inovio Pharmaceuticals received $6.9 million to work with the International Vaccine Institute (IVI) and the Korea National Institute of Health (KNIH) and start Phase 1/2 clinical testing of its INO-4800 vaccine. Following the news, INO stock is up.